MAGEA3 and neoplasm: It is worth mentioning that low-dose DAC can not only significantly improve the expression of NY-ESO-1, MAGE-A3/6, which are important TAAs commonly used as targets for tumor immunotherapy, but also remarkably upregulate the expression of co-stimulatory molecules, major histocompatibility complex (MHC) class I and other immune markers on tumor cells.26,27 These results indicate that low-dose DAC can improve the expression of TAAs and modify the tumor cells to be easily recognized by immune system.